Novavax Inc Stock Price, News & Analysis

Novavax (NASDAQ: NVAX) reported Q3 2025 total revenue of $70M versus $85M a year earlier and a net loss of $202M. The company earned $225M in Sanofi milestones year‑to‑date, including $50M in Q4 2025 related to marketing authorization transfers. Cash totaled $778M as of September 30, 2025.

Key items: R&D $98M with $46M reimbursed by Sanofi; non‑cash charges $126M (including $97M impairment and $29M debt extinguishment loss); Maryland consolidation yields $60M cash and ~$230M expected savings over 11 years. Full‑year adjusted revenue framework raised to $1,040–$1,060M.

Novavax (Nasdaq: NVAX) completed transfer of U.S. marketing authorization for its COVID-19 vaccine Nuvaxovid to Sanofi after receiving U.S. BLA approval, enabling Sanofi to assume U.S. commercial and regulatory responsibility.

The transfer triggered a second $25 million milestone payment and follows an October 2025 EU transfer, contributing to $225 million of non-dilutive milestone revenue secured year-to-date 2025. Novavax remains eligible for additional milestone payments and royalties under the collaboration and license agreement related to Nuvaxovid, combination products and Matrix-M adjuvant use.

Novavax (Nasdaq: NVAX) will report its third quarter 2025 financial results and operational highlights on November 6, 2025 at 8:30 a.m. ET.

Investors can join the live conference call by registering for an automated callback or dialing the listed numbers. A live webcast and replay will be available at ir.novavax.com/events. The teleconference replay is available from 11:30 a.m. ET on November 6, 2025 until 11:59 p.m. ET on November 13, 2025, and the webcast replay will remain on the investor site until December 5, 2025.

Novavax (Nasdaq: NVAX) executed definitive agreements to transfer one Maryland facility and sell adjacent property, generating $60 million in payments and supporting a planned site consolidation.

The company expects $230 million of future cost savings over 11 years from lower lease expense and facility operating costs. Assignment of the facility lease and sale of related assets are expected to close in January 2026 producing $40 million, while sale of adjacent property is expected to close in Q4 2025 producing $20 million. Novavax headquarters will remain in Gaithersburg, Maryland.

Novavax (Nasdaq: NVAX) completed transfer of the EU marketing authorization for its COVID-19 vaccine Nuvaxovid to Sanofi on Oct 7, 2025, triggering a $25 million milestone payment to Novavax and advancing the companies' collaboration and license agreement.

Novavax remains eligible for additional milestones and tiered royalties including a $25 million U.S. transfer milestone, a $75 million technology-transfer milestone, up to $350 million for certain Sanofi combination-product milestones, up to $200 million for the first four Matrix-M products, and ongoing royalties on sales.

Novavax (Nasdaq: NVAX) has expanded its collaboration with Sanofi through an amended license agreement for Novavax's Matrix-M® adjuvant. The amendment allows Sanofi to use Matrix-M in their pandemic influenza vaccine candidate program through Phase 2 development, supported by BARDA funding.

Under the original agreement terms, Novavax can receive up to $200 million for the first four Sanofi products using Matrix-M, and up to $210 million in milestone payments for each subsequent product, plus ongoing royalties. The companies will negotiate additional terms if Sanofi proceeds to Phase 3 development.

Novavax (NASDAQ:NVAX) has announced that its COVID-19 vaccine Nuvaxovid® has received regulatory approval in Japan, triggering a milestone payment from Takeda. The vaccine is approved for initial immunization in ages 6+ and booster shots for ages 12+, specifically formulated to target the SARS-CoV-2 Omicron LP.8.1 variant.

The approval grants Novavax access to Japan's healthcare market, the world's third-largest. Under the collaboration agreement with Takeda, Novavax will receive undisclosed milestone payments and royalties on net sales, with a portion of the milestone payment applicable to future royalty payments.

Novavax (Nasdaq: NVAX) announced its participation in the upcoming Cantor Global Healthcare Conference. The company will engage in a fireside chat on Thursday, September 4, 2025, at 10:20 a.m. ET in New York, NY.

Investors can access the presentation through a webcast on the Events & Presentations page at ir.novavax.com, with replay availability for 30 days following the event.

Novavax (NASDAQ:NVAX) has received FDA approval for its Nuvaxovid™ 2025-2026 Formula, the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. The vaccine is approved for adults aged 65 and older and individuals 12-64 years with high-risk conditions.

Clinical and preclinical data demonstrate the vaccine's effectiveness against currently circulating JN.1 lineage strains, including NB.1.8.1, LP.8.1, XFG, XFC, LF.7, and XEC. Sanofi will lead commercialization efforts, with Novavax receiving tiered royalties from vaccine sales.

The vaccine's safety profile includes warnings for potential side effects such as myocarditis, pericarditis, and common reactions like injection site tenderness and fatigue.